Bio-Techne Collaborates with Luminary to Utilize TcBuster in the Development of CAR-T cell Therapies
Shots:
- The companies signed a license agreement to deploy TcBuster for the manufacturing of gene-modified cell therapies
- Luminary gets a non-exclusive license for TcBuster and will use it in the LMY-920 program. Luminary plans to file an IND with the FDA in late 2021
- The license agreement will allow Bio-Techne to increase its presence in the cell and gene therapy market
Ref: PRNewswire | Image: Owler
Click here to read the full press release
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com
